Literature DB >> 2415971

Suppression of retroviral propagation and disease by suramin in murine systems.

R M Ruprecht, L D Rossoni, W A Haseltine, S Broder.   

Abstract

Retroviral propagation crucially depends on reverse transcriptase (RT). We have developed murine models to test the biological effectiveness of the RT inhibitor suramin. The drug was active in our assay system, which includes (i) inhibition of RT activity in the murine T-cell tropic virus SL3-3 and Rauscher murine leukemia virus (MuLV), (ii) inhibition of plaque formation in the XC plaque assay, (iii) inhibition of viral infection of cultured murine T cells, and (iv) inhibition of splenomegaly induced by Rauscher MuLV in BALB/c mice. Suramin decreases viral titers significantly, even if started 36 hr after infection. Viral titers and number of infected cells increased to control levels after removal of the drug. BALB/c mice treated i.v. with 40 mg of suramin per kg twice per week following infection with Rauscher MuLV showed a 35% decrease in splenomegaly. Suramin is an active antiretroviral agent whose effect on retroviral propagation is reversible. We conclude that it acts as a virustatic drug and that long-term administration of suramin will be necessary if it is used for experimental treatment of human retroviral illnesses such as the acquired immune deficiency syndrome.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415971      PMCID: PMC391408          DOI: 10.1073/pnas.82.22.7733

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  STUDIES WITH THE MURINE LEUKEMOGENIC RAUSCHER VIRUS. 3. AN IN VIVO ASSAY FOR ANTI-VIRAL AGENTS.

Authors:  M A CHIRIGOS
Journal:  Cancer Res       Date:  1964-07       Impact factor: 12.701

2.  Novel leukaemogenic retroviruses isolated from cell line derived from spontaneous AKR tumour.

Authors:  F S Pedersen; R L Crowther; D Y Tenney; A M Reimold; W A Haseltine
Journal:  Nature       Date:  1981-07-09       Impact factor: 49.962

3.  Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses.

Authors:  E De Clercq
Journal:  Cancer Lett       Date:  1979-11       Impact factor: 8.679

4.  HTLV-III infection in brains of children and adults with AIDS encephalopathy.

Authors:  G M Shaw; M E Harper; B H Hahn; L G Epstein; D C Gajdusek; R W Price; B A Navia; C K Petito; C J O'Hara; J E Groopman
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

5.  Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan.

Authors:  V S Kalyanaraman; M G Sarngadharan; Y Nakao; Y Ito; T Aoki; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

6.  Adult T-cell lymphoma-leukaemia in Blacks from the West Indies.

Authors:  D Catovsky; M F Greaves; M Rose; D A Galton; A W Goolden; D R McCluskey; J M White; I Lampert; G Bourikas; R Ireland; A I Brownell; J M Bridges; W A Blattner; R C Gallo
Journal:  Lancet       Date:  1982-03-20       Impact factor: 79.321

7.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

8.  Expression of Ia antigens on myeloid progenitor cells in chronic myeloid leukemia: direct analysis using partially purified colony-forming cells.

Authors:  S A Cannistra; J F Daley; P Larcom; J D Griffin
Journal:  Blood       Date:  1985-02       Impact factor: 22.113

9.  Suppression of the humoral antibody response in natural retrovirus infections.

Authors:  Z Trainin; D Wernicke; H Ungar-Waron; M Essex
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  5 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent.

Authors:  J Balzarini; L Naesens; P Herdewijn; I Rosenberg; A Holy; R Pauwels; M Baba; D G Johns; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  3'-Azido-3'-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening.

Authors:  H Ohnota; Y Okada; H Ushijima; T Kitamura; K Komuro; T Mizuochi
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Vaccination with a live retrovirus: the nature of the protective immune response.

Authors:  R M Ruprecht; S Mullaney; L D Bernard; M A Gama Sosa; R C Hom; R W Finberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  An ELISA system for evaluating antiretroviral activity against Rauscher murine leukemia virus.

Authors:  M G Hollingshead; L Westbrook; M J Ross; J Bailey; K J Qualls; L B Allen
Journal:  Antiviral Res       Date:  1992-06       Impact factor: 5.970

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.